Investors and analysts are getting antsy as AtriCure awaits word from FDA regarding its Convergent hybrid ablation procedure for atrial fibrillation

FDA authorized the IpsiHand System for use in chronic stroke patients to facilitate muscle re-education through its brain-computer interface platform.

Applying specific electric pulses near targeted cells—and using appropriately designed equipment and electrodes—can enhance ablation, chemotherapy, and drug-delivery procedures.

The Lexington, MA-based company is developing a therapy that uses ablation to ablate a portion of the duodenum mucosa, which could have the potential to improve glucose control in patients struggling to manage diabetes.

Cordis is recalling its Precise Pro Rx US Carotid System because of a risk of separation of the atraumatic distal tip of the sheathed delivery system in patients. There have been seven complaints, including five reported injuries, but no deaths...

UNCOVER is a sub-study of LivaNova’s RECOVER study and will deploy technology-enabled research tools from Verily to evaluate the real-world effectiveness of VNS Therapy as an adjunctive treatment for difficult-to-treat depression.

Technology alone cannot create winning combination devices. Devices must be designed to support safe and effective use and to mitigate use errors.

Pressed for time? Here's the medtech news you need most, in one minute or less.